AN2 Therapeutics
novel mechanism of action inhibits the protein synthesis enzyme leucyl by binding to the terminal adenosine ribose of in the editing site leucine in site poet an therapeutics | AN2 Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2022
Slide
14 of 27
Similar slides by AN2 Therapeutics
See diffirences between slides (animation)
Investor Presentation
August 2022
novel mechanism of action inhibits the protein synthesis enzyme leucyl by binding to the terminal adenosine ribose of in the editing site leucine an an therapeutics | AN2 Therapeutics
Other recent decks by AN2 Therapeutics
See all presentations (2 decks)
Investor Presentation
August 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io